This Report includes

Executive Summary
Infographic Overview
Interactive Databook
Report PDF
PowerPoint Presentation
Previous Editions

Make It Custom Enquiry Before Buying

The global Point-of-Care (POC) Diagnostics market is experiencing sustained momentum as healthcare systems, payers, and patients demand faster results, decentralized testing, and clinically actionable insights at or near the site of care. As of 2025, the market size is estimated at approx USD 45 billion, with an expected CAGR of around 9% over the next five years, driven by expanded use cases beyond acute infectious diseases into chronic disease management, cardiometabolic risk assessment, women’s health, oncology adjunct testing, and antimicrobial stewardship. POC testing offers reduced turnaround time, improved patient adherence, fewer follow-up visits, and better triage and care-pathway efficiency—benefits that appeal to hospitals, ambulatory centers, urgent care clinics, pharmacies, and the growing at-home testing category.

POC technologies have advanced considerably from basic lateral flow assays to connected immunoassay platforms, isothermal and CRISPR-based molecular diagnostics, and microfluidic lab-on-a-chip systems. These advances enable greater sensitivity, multiplexing, and real-time data capture. Meanwhile, the legacy impact of respiratory pandemics expanded public and provider familiarity with near-patient testing, catalyzing investment in rapid molecular platforms, pharmacy-based diagnostics, and digital readers integrated into care management systems. In parallel, value-based care and capacity constraints in centralized labs are increasing the strategic importance of POC testing for clinical operations and cost containment.

Point of Care Diagnostics Market Drivers and Emerging Trends

Care decentralization and convenience care
- Shift of diagnostics toward primary care, pharmacies, and home settings to reduce burden on hospitals and improve access.
- Growth of telehealth and remote patient monitoring ecosystems that integrate POC results into clinical workflows.
Clinical and economic imperatives
- Faster decision-making at the point of care improves antimicrobial stewardship and reduces unnecessary admissions.
- Payers incentivize rapid triage and early diagnosis to reduce downstream costs.
Technology maturation
- Around three pivotal technology arcs: high-sensitivity immunoassays, sample-to-answer molecular platforms, and microfluidic lab-on-a-chip systems enabling multiplex testing from small sample volumes.
- AI-enabled readers standardize result interpretation, minimize operator error, and facilitate longitudinal analytics.
Connectivity and data integration
- Growth of Bluetooth- and cloud-connected analyzers for automatic result capture into EHRs, LIS, and population health dashboards.
- Real-time quality control, device management, and compliance reporting across distributed networks.
Pharmacy-based and at-home testing
- Pharmacies evolve into accessible diagnostic hubs for flu, strep, COVID-19, and cardiometabolic screening.
- Consumer familiarity with rapid tests drives demand for convenient home use, with clinical-grade confirmatory pathways.
Regulatory alignment and quality standards
- CLIA-waived pathways in the U.S. and evolving European IVDR frameworks encourage high-quality near-patient devices with robust clinical evidence and post-market surveillance.
Post-pandemic portfolio rebalance
- Diversification from single-pathogen respiratory tests into panels (respiratory, GI, STI), chronic disease markers, and women’s health to sustain growth.

Point of Care Diagnostics Market Segmentation

By Product/Assay Type
- Glucose monitoring and diabetes care (glucose meters, continuous glucose monitoring readers, HbA1c POC)
- Infectious disease tests (respiratory panels, strep A, influenza, COVID-19, RSV, HIV, hepatitis, TB)
- Cardiometabolic markers (troponin, BNP/NT-proBNP, lipid profile, D-dimer)
- Women’s health and fertility (pregnancy tests, ovulation, preeclampsia screening)
- Hematology and coagulation (INR, PT, hemoglobin/hematocrit)
- Urinalysis and renal function (albumin, creatinine)
- Drugs of abuse testing
- Oncology adjunct markers (FIT for colorectal screening, PSA aids; emerging liquid biopsy proxies near care)
By Technology/Platform
- Lateral flow immunoassays (qualitative and semi-quantitative, increasingly with optical/AI readers)
- Immunoassay analyzers (fluorescence immunoassay, chemiluminescence POC)
- Molecular diagnostics (isothermal amplification, rapid PCR, CRISPR-based detection)
- Microfluidics and lab-on-a-chip (multiplex panels from minimal sample)
- Biosensors and electrochemical detection (real-time metabolism and analyte sensing)
By Sample Type
- Capillary whole blood and venous blood
- Nasal/nasopharyngeal and saliva swabs
- Urine and stool (including FIT)
- Others: breath, oral fluid, and emerging non-invasive specimens
By End User
- Hospitals and emergency departments
- Primary care and specialist clinics
- Pharmacies and retail clinics
- Ambulatory surgery centers and urgent care facilities
- Home and community health settings
- Public health programs and field settings
By Region
- North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Key Players in the Point of Care Diagnostics Market

The competitive landscape includes diversified diagnostics majors, focused POC specialists, and innovative startups expanding test menus and connectivity. Representative companies include:

Abbott
Roche Diagnostics
Siemens Healthineers
Danaher (Cepheid, Beckman Coulter)
BD (Becton, Dickinson and Company)
QuidelOrtho
bioMérieux
Thermo Fisher Scientific
Hologic (near-patient women’s health segments)
OraSure Technologies
Nova Biomedical
Sysmex
SD Biosensor
ACON Laboratories
Cue Health
LumiraDx
Mesa Biotech (Thermo Fisher)
Trinity Biotech
EKF Diagnostics
SEKISUI Diagnostics

Competitive priorities center on clinical accuracy, speed to result, breadth of menu, total cost of ownership, connected ecosystem support, and robust evidence packages for regulatory and payer adoption. Partnerships with pharmacy chains, telehealth platforms, and EHR vendors are increasingly decisive.

Research & Development Hotspots of Point of Care Diagnostics

Rapid molecular innovations
- Isothermal chemistries, integrated sample prep, and miniaturized optics driving near-lab sensitivity with under-30-minute turnaround times.
- CRISPR-based detection for highly specific, low-copy number targets and potential multiplexing.
Microfluidics and multiplex panels
- Lab-on-a-chip designs enabling syndromic testing (respiratory, GI, STI) from tiny samples with automated workflow and minimal steps.
AI-assisted readers and analytics
- Computer vision improves line detection in lateral flow devices, reduces invalids, and allows semi-quantitative output.
- Predictive models combine POC results with vitals and patient history to guide decision support.
Connectivity and cybersecurity
- Encrypted data transmission, device fleet management, and automated QC logs for CLIA/IVDR compliance across distributed networks.
Non-invasive sampling
- Saliva, breath, and interstitial fluid monitoring (e.g., glucose) to improve comfort and adherence, with ongoing work to match blood-equivalent accuracy.
Antimicrobial stewardship and resistance testing
- Rapid ID and targeted resistance markers at POC to support appropriate antibiotic selection within a single visit.
Manufacturing scalability and sustainability
- R&D on biodegradable assay materials, reduced plastic usage, and modular instrument designs to lower environmental footprint and cost.

Regional Market Dynamics of Point of Care Diagnostics

North America
- Approx market leadership supported by strong reimbursement frameworks, CLIA-waived pathways, and adoption by retail clinics and pharmacies.
- High penetration of connected analyzers and expanding at-home chronic disease testing programs.
Europe
- Demand driven by primary care networks and hospital stewardship programs; transition to IVDR emphasizes clinical evidence, traceability, and post-market vigilance.
- Diverse country-level payer policies influence pace of pharmacy-based testing adoption.
Asia Pacific
- Around the fastest-growing region, propelled by healthcare access expansion, government screening initiatives, and domestic manufacturing capabilities in cost-sensitive segments.
- Significant opportunities in decentralized infectious disease control and diabetes management.
Latin America
- Growth in private clinics and pharmacy chains; public sector tenders emphasize affordability, robustness, and supply continuity for infectious disease and maternal health.
Middle East & Africa
- POC testing plays a critical role in remote and resource-limited settings; donor-funded programs and national strategies support HIV, TB, and malaria testing scale-up.
- Increasing interest in cardiometabolic and women’s health screening as non-communicable diseases rise.

Point of Care Diagnostics - Strategic Recommendations for Industry Stakeholders

Build a balanced test menu
- Pair high-volume staples (glucose, pregnancy, strep/flu/COVID-19) with higher-value cardiometabolic, women’s health, and targeted molecular panels to smooth seasonal demand.
Prioritize connectivity and compliance
- Offer seamless EHR/LIS integration, remote device management, and automated QC documentation to reduce operational friction for distributed providers.
Optimize for pharmacy and home channels
- Design CLIA-waived, simple workflow devices with clear instructions, built-in readers, and app-based guidance to enable pharmacy staff and consumers.
Invest in evidence and health economics
- Generate real-world data that quantifies avoided visits, reduced antibiotic misuse, and improved outcomes to support payer value cases and formulary inclusion.
Localize for growth markets
- Calibrate pricing, packaging, and service models for Asia Pacific, Latin America, and Africa; strengthen local partnerships for distribution, training, and maintenance.
Advance manufacturing resilience
- Secure multi-source supply chains and flexible capacity to handle demand spikes; implement sustainability initiatives that appeal to health systems’ ESG goals.
Pursue targeted M&A and alliances
- Combine assay developers, instrument makers, and data platform partners to deliver integrated POC ecosystems.
Double down on quality systems
- Ensure robust design controls, lot-to-lot consistency, and post-market surveillance to meet IVDR and global regulatory expectations.

Conclusion

The Point-of-Care Diagnostics market is entering a scale phase where speed, accuracy, connectivity, and clinical utility converge to transform everyday care pathways. With an estimated market size of approx USD 45 billion and strong double-digit potential in select subsegments, leaders will differentiate through comprehensive menus, seamless digital integration, and compelling evidence of cost and outcome benefits. According to Global Infi Research, the strategic path forward is clear: prioritize connected, user-centric platforms; expand into pharmacy and home settings; localize for high-growth regions; and invest in R&D that brings rapid molecular accuracy and multiplexing to the front lines of care. Organizations that execute on these pillars will be well-positioned to capture outsized value as POC testing becomes a foundational layer of modern, decentralized healthcare.

Executive Summary
- Snapshot of market size (approx, base year 2024) and growth outlook through 2030
- Key trends shaping decentralized and near-patient testing
- Summary of market segmentation and leading players
- Strategic highlights for stakeholders
Research Methodology
- Scope and Definitions
  - Market boundaries (products, technologies, end users, settings of care)
  - Inclusion/exclusion criteria and currency/volume assumptions
- Data Sources and Validation
  - Primary research (expert interviews across providers, labs, payers, OEMs)
  - Secondary data (regulatory databases, company disclosures, clinical guidelines)
  - Forecasting approach (top‑down and bottom‑up triangulation; scenario ranges)
Market Overview
- Market Size and Forecast (2021–2030) with base year 2024
  - Historical context (2021–2024) and approx CAGR outlook to 2030
  - Demand inflection points: respiratory testing normalization, chronic care expansion
- Value Chain Analysis
  - Consumables, instruments, software/connectivity, distribution, service
  - Role of pharmacies, retail clinics, and home testing fulfillment
- Technology Roadmap
  - Lateral flow evolution with digital readers
  - Rapid molecular (isothermal, near‑PCR), microfluidics, and multiplexing
  - Connectivity layers (EHR/LIS integration, cloud dashboards, device management)
Market Drivers, Restraints, and Opportunities
- Drivers: care decentralization, time-to-result, payer incentives, antimicrobial stewardship
- Restraints: variability in sensitivity/specificity, reimbursement gaps, workflow training
- Opportunities: pharmacy and home channels, syndromic panels, AI readers, emerging markets
In-Depth Market Segmentation
- By Product/Assay Type
  - Glucose monitoring and diabetes care (glucose meters, HbA1c POC)
  - Infectious disease testing (respiratory, strep A, influenza, COVID-19, RSV, HIV, hepatitis, TB)
  - Cardiometabolic markers (troponin, BNP/NT‑proBNP, lipid profile, D‑dimer)
  - Women’s health and fertility (pregnancy, ovulation, preeclampsia screening)
  - Hematology and coagulation (INR/PT, hemoglobin/hematocrit)
  - Urinalysis and renal function (albumin, creatinine)
  - Drugs of abuse testing
  - Oncology adjunct markers (e.g., FIT, PSA aids)
- By Technology/Platform
  - Lateral flow immunoassays (qualitative/semi‑quantitative with optical/AI readers)
  - Fluorescence/chemiluminescence immunoassay analyzers
  - Molecular diagnostics (isothermal amplification, rapid PCR, CRISPR‑based)
  - Microfluidics and lab‑on‑a‑chip (multiplex panels)
  - Biosensors and electrochemical detection
- By Sample Type
  - Capillary/venous blood; nasal/nasopharyngeal and saliva; urine; stool; oral fluid/breath
- By End User
  - Hospitals/ED, primary and specialty clinics, pharmacies/retail clinics, urgent care/ASCs, home settings, public health/field programs
- By Setting of Care
  - Near‑patient in clinical settings, pharmacy‑based testing, at‑home/remote monitoring
- By Region
  - North America, Europe, Asia‑Pacific, Middle East & Africa, Latin America
Regional Market Dynamics
- North America: reimbursement and CLIA‑waived adoption; pharmacy channel expansion
- Europe: IVDR compliance, primary care integration, country‑level reimbursement variation
- Asia‑Pacific: fastest growth, screening initiatives, domestic manufacturing scale
- Middle East & Africa: access in remote settings, donor‑supported programs, NCD screening
- Latin America: private clinic/pharmacy growth, cost-sensitive tenders, supply resilience
Key Players in the Market
- Global Leaders
  - Abbott; Roche Diagnostics; Siemens Healthineers; Danaher (Cepheid, Beckman Coulter); BD
- Established POC Specialists
  - QuidelOrtho; bioMérieux; Thermo Fisher Scientific; Hologic (near‑patient segments)
  - Nova Biomedical; Sysmex; Trinity Biotech; EKF Diagnostics; SEKISUI Diagnostics
- High-Growth and Niche Innovators
  - SD Biosensor; ACON Laboratories; OraSure Technologies; Cue Health; LumiraDx; Mesa Biotech
- Competitive Landscape Summary
  - Portfolio breadth, menu expansion, connectivity, TCO, evidence and regulatory positioning
  - Partnerships with pharmacies, telehealth platforms, and EHR/LIS vendors
Research & Development Hotspots
- Rapid molecular and CRISPR‑based assays; microfluidic multiplex panels
- AI/computer vision readers and semi‑quantitative lateral flow
- Connectivity, cybersecurity, and fleet management at scale
- Non‑invasive sampling and real‑time biosensing; sustainability in consumables
Regulatory and Sustainability Framework
- U.S. CLIA‑waived pathways; EU IVDR requirements and post‑market vigilance
- Quality systems, real‑world performance evidence, UDI/traceability
- Environmental considerations: recyclable materials, reduced plastics, packaging optimization
Strategic Recommendations

Menu strategy: balance high‑volume SKUs with higher‑value cardiometabolic and women’s health
Channel strategy: pharmacy and home enablement; training and UX simplification
Digital strategy: interoperability, remote QC, automated reporting, analytics
Market entry/localization: pricing and service models tailored for APAC, LATAM, MEA
Partnership/M&A: assay‑instrument‑software ecosystems; supply chain resilience

Appendix

Glossary
List of Abbreviations
Contact Information – Global Infi Research

Point of Care Diagnostics Market

$2499